Those are some compelling arguments and I have str
Post# of 148185
While I agree that BP has and will continue to have a significant influence on the FDA and smaller biotechs, CytoDyn and leronlimab are not your typical biotech company or drug. It is rare to see a small company (much less OTC) make the transition from pre-revenue to even mid-market player. I don’t know that we will get there, but if there was ever a chance leronlimab has the ability to make this dream come true.....and if time runs out and BP scoops it up, the CytoDyn dream will die but leronlimab will still save many lives and make a lot of us millionaires in the process.
Best of luck and I hope everyone has a safe weekend.